IGHE and skin reaction: From the same trial, we now present the difference in treatment efficacy between patients treated with SQ-standardized HDM SCIT plus ICS and patients treated with placebo plus ICS in terms of nonspecific and HDM-allergen-specific BHR, late asthmatic reaction (LAR), lung function, HDM-allergen-specific immediate- and late-phase skin reactions and immunological response (HDM-allergen-specific IgE and IgE-blocking factor).